Subscribe To
PGEN / Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
PGEN News
By Zacks Investment Research
September 5, 2023
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-da more_horizontal
By Seeking Alpha
August 9, 2023
Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor more_horizontal
By InvestorPlace
May 19, 2023
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich
High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risk more_horizontal
By Zacks Investment Research
March 14, 2023
Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to th more_horizontal
By PennyStocks
March 7, 2023
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Sto more_horizontal
By The Motley Fool
February 16, 2023
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. more_horizontal
By PennyStocks
February 6, 2023
3 Penny Stocks To Buy According To Insider Bets Up To $25 Million
Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared firs more_horizontal
By Zacks Investment Research
January 27, 2023
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal